THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS
The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Two alternative catabolic routes exist: oxidation...
Gespeichert in:
Veröffentlicht in: | Transplantation 1992, Vol.53 (5), p.1051-1056 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1056 |
---|---|
container_issue | 5 |
container_start_page | 1051 |
container_title | Transplantation |
container_volume | 53 |
creator | CHOCAIR, PR DULEY, JA SIMMONDS, HA CAMERON, JS |
description | The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Two alternative catabolic routes exist: oxidation to 6-thiouric acid via xanthine oxidase and methylation to 6-methylmercaptopurine via the enzyme thiopurine methyltransferase (TPMT). Catabolism via either route would restrict formation of the active metabolites.
We analyzed TPMT activity in erythrocyte lysates of 25 controls, 25 uremic patients on dialysis, and 68 transplanted patients. Median activity was lower in controls (31.0 pmol/hr/mg Hb, range 16.2-43.0) and transplanted patients receiving only cyclosporine and prednisolone (31.7 pmol/hr/mg Hb, range 12.7-43.5) than in the azathioprine treated group, (36.1 pmol/hr/mg Hb, range 16.1-71.3), or the uremic group on dialysis, (35.5 pmol/hr/mg Hb, range 18.6-62.6) suggesting that both azathioprine and uremia induce the enzyme, but CsA does not.
Only 3 patients demonstrated total intolerance to azathioprine, 2 of whom had very low TPMT activity (zero and 12.7 pmol/hr/mg Hb). The intolerance of the third patient, despite high TPMT activity, was attributed to concomitant cotrimoxazole therapy. Patients with intermediate activity (15-26 pmol/hr/mg Hb) could tolerate azathioprine well.
Of 29 cadaver recipients given only azathioprine plus prednisolone, 24 with a better clinical outcome had a significantly lower activity (33.1 pmol/hr/mg Hb, range 16.1-46.1) than 5 with reduced allograft function (42.5 pmol/hr/mg Hb, range 33.8-51.5). TPMT activity in these 24 patients was also significantly lower than the general group of azathioprine-treated recipients.
This inverse association between TPMT activity and allograft function was again found among 30 patients receiving triple therapy (azathioprine, CsA, prednisolone). Self-selection of the best recipients for azathioprine immunosuppression apparently occurred, based on low catabolism of the drug.
We conclude that total intolerance to azathioprine is rare and usually appears in patients with very low TPMT activities. Our results also suggest that the wide range of TPMT activity may be an important factor in determining long-term graft survival in azathioprine-treated patients; those with high activity might benefit from doses near the upper limit generally recommended. |
doi_str_mv | 10.1097/00007890-199205000-00016 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_1585469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16325274</sourcerecordid><originalsourceid>FETCH-LOGICAL-j361t-37a2d82b2e6b6bf938b61ea39d45367fe29b263c8823854f397c2d4f1b8b12983</originalsourceid><addsrcrecordid>eNqNkV1r2zAUhsXY6LJuP2Ggi7Gb4k0ftj4uhVFmQWoHRxl0N0FyZHBx7C5yGPv3c93Q6wkOQrzPc0DnAAAx-oaR5N_RfLiQKMFSEpTNr2QuzN6AFc5omjAk0FuwQijFCaaUvwcfYnyckYxyfgNucCaylMkV6G2hobnfVrVVZa5htYa2MNV2X5tSw3tti4eNrVW5W-ta7TRUuTU_jX2A66qGz-5-t0jql1q8RTMlXJztRpUW1jo3W6NLu_sI3rWuj-HT9b4F-7W2eZFsqh8mV5vkkTI8JZQ7chTEk8A8862kwjMcHJXHNKOMt4FITxhthCB0_kZLJW_IMW2xFx4TKegt-PrS9-k8_r6EOB1OXWxC37shjJd4wIySjPB0Bj9fwYs_hePh6dyd3Pnv4TqeOf9yzV1sXN-e3dB08RXLKGGpxDN294L9CX5sY9OFoQmvlHreUbEXOF1WNNPi_-m8m9zUjUM-XoaJ_gPsW4yx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16325274</pqid></control><display><type>article</type><title>THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS</title><source>Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>CHOCAIR, PR ; DULEY, JA ; SIMMONDS, HA ; CAMERON, JS</creator><creatorcontrib>CHOCAIR, PR ; DULEY, JA ; SIMMONDS, HA ; CAMERON, JS</creatorcontrib><description>The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Two alternative catabolic routes exist: oxidation to 6-thiouric acid via xanthine oxidase and methylation to 6-methylmercaptopurine via the enzyme thiopurine methyltransferase (TPMT). Catabolism via either route would restrict formation of the active metabolites.
We analyzed TPMT activity in erythrocyte lysates of 25 controls, 25 uremic patients on dialysis, and 68 transplanted patients. Median activity was lower in controls (31.0 pmol/hr/mg Hb, range 16.2-43.0) and transplanted patients receiving only cyclosporine and prednisolone (31.7 pmol/hr/mg Hb, range 12.7-43.5) than in the azathioprine treated group, (36.1 pmol/hr/mg Hb, range 16.1-71.3), or the uremic group on dialysis, (35.5 pmol/hr/mg Hb, range 18.6-62.6) suggesting that both azathioprine and uremia induce the enzyme, but CsA does not.
Only 3 patients demonstrated total intolerance to azathioprine, 2 of whom had very low TPMT activity (zero and 12.7 pmol/hr/mg Hb). The intolerance of the third patient, despite high TPMT activity, was attributed to concomitant cotrimoxazole therapy. Patients with intermediate activity (15-26 pmol/hr/mg Hb) could tolerate azathioprine well.
Of 29 cadaver recipients given only azathioprine plus prednisolone, 24 with a better clinical outcome had a significantly lower activity (33.1 pmol/hr/mg Hb, range 16.1-46.1) than 5 with reduced allograft function (42.5 pmol/hr/mg Hb, range 33.8-51.5). TPMT activity in these 24 patients was also significantly lower than the general group of azathioprine-treated recipients.
This inverse association between TPMT activity and allograft function was again found among 30 patients receiving triple therapy (azathioprine, CsA, prednisolone). Self-selection of the best recipients for azathioprine immunosuppression apparently occurred, based on low catabolism of the drug.
We conclude that total intolerance to azathioprine is rare and usually appears in patients with very low TPMT activities. Our results also suggest that the wide range of TPMT activity may be an important factor in determining long-term graft survival in azathioprine-treated patients; those with high activity might benefit from doses near the upper limit generally recommended.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-199205000-00016</identifier><identifier>PMID: 1585469</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>BALTIMORE: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Adult ; Aged ; Azathioprine - therapeutic use ; Azathioprine - toxicity ; Biological and medical sciences ; Child ; Cyclosporine - therapeutic use ; Female ; Graft Survival - drug effects ; Humans ; Immunology ; Immunomodulators ; Kidney Function Tests ; Kidney Transplantation - immunology ; Leukocyte Count ; Life Sciences & Biomedicine ; Male ; Medical sciences ; Methyltransferases - blood ; Methyltransferases - metabolism ; Middle Aged ; Pharmacology. Drug treatments ; Prednisolone - therapeutic use ; Science & Technology ; Surgery ; Transplantation</subject><ispartof>Transplantation, 1992, Vol.53 (5), p.1051-1056</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>151</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wosA1992HU81400016</woscitedreferencesoriginalsourcerecordid><cites>FETCH-LOGICAL-j361t-37a2d82b2e6b6bf938b61ea39d45367fe29b263c8823854f397c2d4f1b8b12983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,4026,27199,27930,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5326491$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1585469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHOCAIR, PR</creatorcontrib><creatorcontrib>DULEY, JA</creatorcontrib><creatorcontrib>SIMMONDS, HA</creatorcontrib><creatorcontrib>CAMERON, JS</creatorcontrib><title>THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS</title><title>Transplantation</title><addtitle>TRANSPLANTATION</addtitle><addtitle>Transplantation</addtitle><description>The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Two alternative catabolic routes exist: oxidation to 6-thiouric acid via xanthine oxidase and methylation to 6-methylmercaptopurine via the enzyme thiopurine methyltransferase (TPMT). Catabolism via either route would restrict formation of the active metabolites.
We analyzed TPMT activity in erythrocyte lysates of 25 controls, 25 uremic patients on dialysis, and 68 transplanted patients. Median activity was lower in controls (31.0 pmol/hr/mg Hb, range 16.2-43.0) and transplanted patients receiving only cyclosporine and prednisolone (31.7 pmol/hr/mg Hb, range 12.7-43.5) than in the azathioprine treated group, (36.1 pmol/hr/mg Hb, range 16.1-71.3), or the uremic group on dialysis, (35.5 pmol/hr/mg Hb, range 18.6-62.6) suggesting that both azathioprine and uremia induce the enzyme, but CsA does not.
Only 3 patients demonstrated total intolerance to azathioprine, 2 of whom had very low TPMT activity (zero and 12.7 pmol/hr/mg Hb). The intolerance of the third patient, despite high TPMT activity, was attributed to concomitant cotrimoxazole therapy. Patients with intermediate activity (15-26 pmol/hr/mg Hb) could tolerate azathioprine well.
Of 29 cadaver recipients given only azathioprine plus prednisolone, 24 with a better clinical outcome had a significantly lower activity (33.1 pmol/hr/mg Hb, range 16.1-46.1) than 5 with reduced allograft function (42.5 pmol/hr/mg Hb, range 33.8-51.5). TPMT activity in these 24 patients was also significantly lower than the general group of azathioprine-treated recipients.
This inverse association between TPMT activity and allograft function was again found among 30 patients receiving triple therapy (azathioprine, CsA, prednisolone). Self-selection of the best recipients for azathioprine immunosuppression apparently occurred, based on low catabolism of the drug.
We conclude that total intolerance to azathioprine is rare and usually appears in patients with very low TPMT activities. Our results also suggest that the wide range of TPMT activity may be an important factor in determining long-term graft survival in azathioprine-treated patients; those with high activity might benefit from doses near the upper limit generally recommended.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Azathioprine - therapeutic use</subject><subject>Azathioprine - toxicity</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Graft Survival - drug effects</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunomodulators</subject><subject>Kidney Function Tests</subject><subject>Kidney Transplantation - immunology</subject><subject>Leukocyte Count</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methyltransferases - blood</subject><subject>Methyltransferases - metabolism</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisolone - therapeutic use</subject><subject>Science & Technology</subject><subject>Surgery</subject><subject>Transplantation</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EZCTM</sourceid><sourceid>EIF</sourceid><recordid>eNqNkV1r2zAUhsXY6LJuP2Ggi7Gb4k0ftj4uhVFmQWoHRxl0N0FyZHBx7C5yGPv3c93Q6wkOQrzPc0DnAAAx-oaR5N_RfLiQKMFSEpTNr2QuzN6AFc5omjAk0FuwQijFCaaUvwcfYnyckYxyfgNucCaylMkV6G2hobnfVrVVZa5htYa2MNV2X5tSw3tti4eNrVW5W-ta7TRUuTU_jX2A66qGz-5-t0jql1q8RTMlXJztRpUW1jo3W6NLu_sI3rWuj-HT9b4F-7W2eZFsqh8mV5vkkTI8JZQ7chTEk8A8862kwjMcHJXHNKOMt4FITxhthCB0_kZLJW_IMW2xFx4TKegt-PrS9-k8_r6EOB1OXWxC37shjJd4wIySjPB0Bj9fwYs_hePh6dyd3Pnv4TqeOf9yzV1sXN-e3dB08RXLKGGpxDN294L9CX5sY9OFoQmvlHreUbEXOF1WNNPi_-m8m9zUjUM-XoaJ_gPsW4yx</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>CHOCAIR, PR</creator><creator>DULEY, JA</creator><creator>SIMMONDS, HA</creator><creator>CAMERON, JS</creator><general>Lippincott Williams & Wilkins</general><general>Lippincott</general><scope>BLEPL</scope><scope>DTL</scope><scope>EZCTM</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>1992</creationdate><title>THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS</title><author>CHOCAIR, PR ; DULEY, JA ; SIMMONDS, HA ; CAMERON, JS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j361t-37a2d82b2e6b6bf938b61ea39d45367fe29b263c8823854f397c2d4f1b8b12983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Azathioprine - therapeutic use</topic><topic>Azathioprine - toxicity</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Graft Survival - drug effects</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunomodulators</topic><topic>Kidney Function Tests</topic><topic>Kidney Transplantation - immunology</topic><topic>Leukocyte Count</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methyltransferases - blood</topic><topic>Methyltransferases - metabolism</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisolone - therapeutic use</topic><topic>Science & Technology</topic><topic>Surgery</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOCAIR, PR</creatorcontrib><creatorcontrib>DULEY, JA</creatorcontrib><creatorcontrib>SIMMONDS, HA</creatorcontrib><creatorcontrib>CAMERON, JS</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 1992</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOCAIR, PR</au><au>DULEY, JA</au><au>SIMMONDS, HA</au><au>CAMERON, JS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS</atitle><jtitle>Transplantation</jtitle><stitle>TRANSPLANTATION</stitle><addtitle>Transplantation</addtitle><date>1992</date><risdate>1992</risdate><volume>53</volume><issue>5</issue><spage>1051</spage><epage>1056</epage><pages>1051-1056</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Two alternative catabolic routes exist: oxidation to 6-thiouric acid via xanthine oxidase and methylation to 6-methylmercaptopurine via the enzyme thiopurine methyltransferase (TPMT). Catabolism via either route would restrict formation of the active metabolites.
We analyzed TPMT activity in erythrocyte lysates of 25 controls, 25 uremic patients on dialysis, and 68 transplanted patients. Median activity was lower in controls (31.0 pmol/hr/mg Hb, range 16.2-43.0) and transplanted patients receiving only cyclosporine and prednisolone (31.7 pmol/hr/mg Hb, range 12.7-43.5) than in the azathioprine treated group, (36.1 pmol/hr/mg Hb, range 16.1-71.3), or the uremic group on dialysis, (35.5 pmol/hr/mg Hb, range 18.6-62.6) suggesting that both azathioprine and uremia induce the enzyme, but CsA does not.
Only 3 patients demonstrated total intolerance to azathioprine, 2 of whom had very low TPMT activity (zero and 12.7 pmol/hr/mg Hb). The intolerance of the third patient, despite high TPMT activity, was attributed to concomitant cotrimoxazole therapy. Patients with intermediate activity (15-26 pmol/hr/mg Hb) could tolerate azathioprine well.
Of 29 cadaver recipients given only azathioprine plus prednisolone, 24 with a better clinical outcome had a significantly lower activity (33.1 pmol/hr/mg Hb, range 16.1-46.1) than 5 with reduced allograft function (42.5 pmol/hr/mg Hb, range 33.8-51.5). TPMT activity in these 24 patients was also significantly lower than the general group of azathioprine-treated recipients.
This inverse association between TPMT activity and allograft function was again found among 30 patients receiving triple therapy (azathioprine, CsA, prednisolone). Self-selection of the best recipients for azathioprine immunosuppression apparently occurred, based on low catabolism of the drug.
We conclude that total intolerance to azathioprine is rare and usually appears in patients with very low TPMT activities. Our results also suggest that the wide range of TPMT activity may be an important factor in determining long-term graft survival in azathioprine-treated patients; those with high activity might benefit from doses near the upper limit generally recommended.</abstract><cop>BALTIMORE</cop><pub>Lippincott Williams & Wilkins</pub><pmid>1585469</pmid><doi>10.1097/00007890-199205000-00016</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1337 |
ispartof | Transplantation, 1992, Vol.53 (5), p.1051-1056 |
issn | 0041-1337 1534-6080 |
language | eng |
recordid | cdi_pubmed_primary_1585469 |
source | Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; MEDLINE; Journals@Ovid Complete |
subjects | Adolescent Adult Aged Azathioprine - therapeutic use Azathioprine - toxicity Biological and medical sciences Child Cyclosporine - therapeutic use Female Graft Survival - drug effects Humans Immunology Immunomodulators Kidney Function Tests Kidney Transplantation - immunology Leukocyte Count Life Sciences & Biomedicine Male Medical sciences Methyltransferases - blood Methyltransferases - metabolism Middle Aged Pharmacology. Drug treatments Prednisolone - therapeutic use Science & Technology Surgery Transplantation |
title | THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T13%3A11%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THE%20IMPORTANCE%20OF%20THIOPURINE%20METHYLTRANSFERASE%20ACTIVITY%20FOR%20THE%20USE%20OF%20AZATHIOPRINE%20IN%20TRANSPLANT%20RECIPIENTS&rft.jtitle=Transplantation&rft.au=CHOCAIR,%20PR&rft.date=1992&rft.volume=53&rft.issue=5&rft.spage=1051&rft.epage=1056&rft.pages=1051-1056&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-199205000-00016&rft_dat=%3Cproquest_pubme%3E16325274%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16325274&rft_id=info:pmid/1585469&rfr_iscdi=true |